Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
PHASE1CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
March 31, 1998
Study Completion Date
January 31, 2002
Conditions
Colorectal NeoplasmHereditary Nonpolyposis
Interventions
DRUG
Celecoxib (SC-58635)
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001693 - Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers | Biotech Hunter | Biotech Hunter